Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

August 31, 2011

Study Completion Date

November 30, 2011

Conditions
Advanced Solid TumorsLymphoma
Interventions
DRUG

TAK-901

"This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2."

Trial Locations (3)

19046

Fox Chase Cancer Center, Rockledge

48201

Karmanos Cancer Center, Detroit

Unknown

The University of Michigan, Ann Arbor

All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT00935844 - Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma | Biotech Hunter | Biotech Hunter